https://www.selleckchem.com/pr....oducts/paeoniflorin.
Seventy-four percent and 59% were dispensed ≥50% target dose of ACEi/ARB and beta-blocker respectively. Ninety-five percent and 89% were on maximally tolerated doses of ACEi/ARB and beta-blockers respectively. Thirteen percent were potentially eligible for primary prevention implantable cardiac defibrillator; however, only 24% of these eligible patients had one implanted by one year post-discharge. Conclusions Evidence-based HF therapies were underutilised in this regional cohort of patients with reduced LVEF post-ACS. Strategies t
Like
Comment
Share
